

Carpenters Local 491

Express Summary Report

Chris Kelley, PharmD. Sr Clinical Account Executive

09/10/2020

Plan Performance

- Plan Cost PMPM decreased \$26.96 (-27.9%) to \$69.65
- Member Cost decreased 7.9%, contributing \$4.1K less to the plan
- Rebates reduced Plan Cost PMPM from \$69.65 to \$54.64 (-21.6%)

Plan Performance			
	1/20 - 8/20	1/19 - 8/19	Change %
AWP	\$1,178,852	\$1,363,460	-13.5%
Network & Mail Discount			
Savings (includes dispensing fees)	-\$634,136	-\$633,281	0.1%
Tax	\$238	\$262	-9.2%
Gross Cost	\$544,954	\$730,441	-25.4%
Member Cost	-\$48,471	-\$52,602	-7.9%
Plan Cost	\$496,484	\$677,839	-26.8%
Rebates*	-\$107,026	-\$181,668	-41.1%
Plan Cost Net	\$389,458	\$496,171	-21.5%
Members	891	877	1.6%
Plan Cost PMPM	\$69.65	\$96.61	-27.9%
Plan Cost Net PMPM	\$54.64	\$70.72	-22.7%

* Rebates are estimated based on paid and expected to be paid amounts. Actual rebate payments may differ from estimates.



Top Line Performance Metrics

- Plan Cost Net PMPM decreased \$16.08 (-22.7%) to \$54.64, primarily driven by the Unit Cost Trend Component
- Specialty Plan Cost Net PMPM decreased \$14.39 (-35.6%) to \$25.99, primarily driven by the Specialty Unit Cost Trend Component
- Generic Fill Rate (GFR) increased 1 percentage points to 91.1%, 4.2 percentage points higher than the peer

UBC Carpenters Local 491			
Description	1/20 - 8/20	1/19 - 8/19	Change
Avg Subscribers per Month	462	451	2.4%
Avg Members per Month	891	877	1.6%
Number of Unique Patients	443	460	-3.7%
Pct Members Utilizing Benefit	49.7%	52.5%	-2.7
Plan Cost Net	\$389,458	\$496,171	-21.5%
Total Days	167,926	162,172	3.5%
Total Adjusted Rx's	6,340	6,181	2.6%
Average Member Age	40.0	39.6	1.2%
Plan Cost Net PMPM	\$54.64	\$70.72	-22.7%
Plan Cost Net/Day	\$2.32	\$3.06	-24.2%
Plan Cost Net per Adjusted Rx	\$61.43	\$80.27	-23.5%
Nbr Adjusted Rx's PMPM	0.89	0.88	1.0%
Generic Fill Rate	91.1%	90.1%	1.0
90 Day Utilization	51.8%	49.6%	2.1
Retail - Maintenance 90 Utilization	20.7%	17.0%	3.7
Home Delivery Utilization	31.1%	32.7%	-1.6
Member Cost Net %	11.1%	9.6%	1.5
Specialty Percent of Plan Cost Net	47.6%	57.1%	-9.5
Specialty Plan Cost Net PMPM	\$25.99	\$40.38	-35.6%
Formulary Compliance Rate	98.9%	98.8%	0.1

Labor	
1/20 - 8/20	Change
37.2	0.3%
\$122.10	4.4%
\$3.82	2.5%
\$100.46	4.5%
1.22	-0.1%
86.9%	0.7
49.1%	0.4
4.3%	0.8
44.8%	-0.4
8.8%	0.1
44.7%	2.8
\$54.61	11.2%
98.0%	0.0

Key Statistics: Specialty Detailed

- Your Specialty Plan Cost Net PMPM is \$28.62 lower than your peer, and trending 46.9 points lower
- You have 3 unique specialty patients, a decrease of 3 specialty patients


UBC Carpenters Local 491						
Description	Non-Specialty			Specialty		
	1/20 - 8/20	1/19 - 8/19	Change	1/20 - 8/20	1/19 - 8/19	Change
Avg Subscribers per Month	462	451	2.4%	462	451	2.4%
Avg Members per Month	891	877	1.6%	891	877	1.6%
Number of Unique Patients	443	459	-3.5%	3	6	-50.0%
Pct Members Utilizing Benefit	49.7%	52.3%	-2.6	0.3%	0.7%	-0.3
Total Plan Cost Net	\$204,210	\$212,890	-4.1%	\$185,248	\$283,282	-34.6%
Percent of Total Plan Cost Net	52.4%	42.9%	9.5	47.6%	57.1%	-9.5
Total Days	167,181	161,575	3.5%	745	597	24.8%
Total Adjusted Rx	6,315	6,160	2.5%	25	21	19.0%
Percent of Total Adjusted Rx	99.61%	99.66%	-0.1	0.39%	0.34%	0.1
Plan Cost Net PMPM	\$28.65	\$30.34	-5.6%	\$25.99	\$40.38	-35.6%
Plan Cost Net/Day	\$1.22	\$1.32	-7.3%	\$248.65	\$474.51	-47.6%
Plan Cost Net per Adjusted Rx	\$32.34	\$34.56	-6.4%	\$7,409.92	\$13,489.60	-45.1%
Nbr Adjusted Rx PMPM	0.89	0.88	0.9%	0.004	0.003	17.2%
Generic Fill Rate	91.4%	90.4%	1.1	0.0%	0.0%	0.0
Member Cost Net %	18.9%	19.3%	-0.5	0.5%	0.6%	0.0

Specialty Labor	
1/20 - 8/20	Change
\$54.61	11.2%
\$198.41	5.6%
\$5,455.86	6.3%
0.01	4.6%
9.5%	-1.0
4.2%	0.0

Trend Components Plan Cost Net PMPM

Plan Cost
Net PMPM

Your
Trend



Rebates reduced costs by \$107 Thousand



Top 10 Indications

- The largest financially impactful change was in Enzyme Deficiencies, driving \$27.7K in increased net cost from a 24.9% increase in Net PMPM
- Mental/Neuro Disorders trend increased 1028.2%, contributing an additional \$0.98 to Net PMPM
- Generic Fill Rate (GFR) in Pulmonary Hypertension lags your peer by 69.3 points

Represent
91.5%
Of Your Total
Plan Cost Net

Top Indications by Plan Cost Net														
1/20 - 8/20									1/19 - 8/19					% Change
Rank	Peer Rank	Indication	Adjusted Rxs	Patients	Plan Cost Net	Generic Fill Rate	Peer Generic Fill Rate	Plan Cost Net PMPM	Rank	Adjusted Rxs	Patients	Generic Fill Rate	Plan Cost Net PMPM	Plan Cost Net PMPM
1	24	ENZYME DEFICIENCIES	5	1	\$130,970	0.0%	1.4%	\$18.37	1	4	1	0.0%	\$14.71	24.9%
2	23	PULMONARY HYPERTENSION	8	1	\$81,412	0.0%	69.3%	\$11.42	2	8	1	0.0%	\$10.88	5.0%
3	6	HIV	20	2	\$47,729	0.0%	9.0%	\$6.70	3	37	4	0.0%	\$9.80	-31.7%
4	34	CHEMICAL DEPENDENCE	154	20	\$39,072	74.0%	81.8%	\$5.48	4	137	19	53.3%	\$4.48	22.4%
5	8	PAIN/INFLAMMATION	619	152	\$14,472	96.6%	97.5%	\$2.03	5	724	166	94.5%	\$2.85	-28.7%
6	2	DIABETES	280	30	\$10,313	63.9%	44.5%	\$1.45	22	297	35	67.0%	\$0.28	424.5%
7	16	SEIZURES	109	16	\$10,065	94.5%	93.6%	\$1.41	18	141	15	100.0%	\$0.35	308.7%
8	10	SKIN CONDITIONS	77	39	\$7,740	85.7%	88.8%	\$1.09	7	67	44	91.0%	\$0.90	20.8%
9	13	MENTAL/NEURO DISORDERS	68	11	\$7,689	89.7%	89.6%	\$1.08	42	47	12	100.0%	\$0.10	1028.2%
10	20	CONTRACEPTIVES	160	25	\$6,741	74.4%	88.7%	\$0.95	6	129	23	69.8%	\$0.93	1.8%
Total Top 10:			1,500		\$356,202	82.7%		\$49.97		1,591		81.4%	\$45.26	10.4%
Differences Between Periods:			-91		\$38,678	1.3%		\$4.72						

Peer = Express Scripts Peer 'Labor' market segment



Top 25 Drugs

- Represent 81.7% of your total Plan Cost Net and comprise 16 indications
- 2 of your top 25 are specialty drugs, making up 60.3% of your Top 25 spend

Top Drugs by Plan Cost Net														
1/20 - 8/20								1/19 - 8/19				% Change		
Rank	Peer Rank	Brand Name	Indication	Adj. Rx	Pts.	Plan Cost Net	Plan Cost Net PMPM	Rank	Adj. Rx	Pts.	Plan Cost Net PMPM	Plan Cost Net PMPM		
1	544	GALAFOLD*	ENZYME DEFICIENCIES	5	1	\$130,970	\$18.37	1	4	1	\$14.71	24.9%		
2	213	ADEMPAS*	PULMONARY HYPERTENSION	8	1	\$81,412	\$11.42	2	8	1	\$10.88	5.0%		
3	70	BUPRENORPHINE-NALOXONE	CHEMICAL DEPENDENCE	75	12	\$25,805	\$3.62	8	48	12	\$2.50	44.5%		
4	260	SYM TUZA	HIV	7	1	\$24,726	\$3.47							
5	40	DESCOVY	HIV	7	2	\$11,692	\$1.64	5	15	2	\$3.29	-50.1%		
6	329	PREZCOBIX	HIV	6	2	\$11,311	\$1.59	4	15	2	\$3.86	-58.9%		
7	95	VIMPAT	SEIZURES	6	1	\$8,307	\$1.17							
8	586	BUPRENORPHINE HCL	CHEMICAL DEPENDENCE	31	4	\$5,570	\$0.78	15	25	4	\$0.49	60.2%		
9	85	CHANTIX	SMOKING CESSATION	12	8	\$5,062	\$0.71	13	11	8	\$0.63	13.5%		
10	90	REXULTI	MENTAL/NEURO DISORDERS	5	1	\$4,971	\$0.70							
11	153	SUBOXONE	CHEMICAL DEPENDENCE	19	3	\$4,670	\$0.66	10	56	12	\$1.02	-35.8%		
12	259	NUCYNTA	PAIN/INFLAMMATION	21	1	\$4,134	\$0.58	11	18	1	\$0.64	-9.1%		
13	3	TRULICITY	DIABETES	13	2	\$4,104	\$0.58	24	6	1	\$0.23	145.2%		
14	71	TRELEGY ELLIPTA	COPD	17	4	\$3,656	\$0.51	117	7	3	\$0.04	1276.3%		
15	80	LO LOESTRIN FE	CONTRACEPTIVES	29	5	\$3,267	\$0.46	16	33	5	\$0.48	-5.0%		
16	655	ZUBSOLV	CHEMICAL DEPENDENCE	24	2	\$2,902	\$0.41	17	8	1	\$0.46	-12.2%		
17	435	OXYCODONE HCL	PAIN/INFLAMMATION	83	18	\$2,603	\$0.37	14	132	26	\$0.51	-28.6%		
18	169	SHINGRIX	VACCINATIONS	15	14	\$2,489	\$0.35	56	5	3	\$0.12	203.3%		
19	12	JARDIANCE	DIABETES	13	3	\$2,448	\$0.34	54	6	1	\$0.12	191.0%		
20	4	ELIQUIS	ANTICOAGULANT	11	5	\$2,245	\$0.31	12	22	4	\$0.63	-49.7%		
21	803	DUOBRII	SKIN CONDITIONS	3	1	\$2,197	\$0.31							
22	81	VRAYLAR	MENTAL/NEURO DISORDERS	2	1	\$2,173	\$0.30							
23	358	SOOLANTRA	SKIN CONDITIONS	4	1	\$1,976	\$0.28							
24	229	RANOLAZINE ER	HEART DISEASE	6	1	\$1,782	\$0.25	50	3	1	\$0.13	88.1%		
25	799	ENTECAVIR	OTHER HEPATITIS	7	1	\$1,732	\$0.24	20	9	1	\$0.32	-23.4%		
		Total Top 25:		429		\$352,204	\$49.41		431		\$41.06	20.3%		
		Differences Between Periods:		-2		\$64,150	\$8.35							

*Specialty Drugs

Peer = Express Scripts Peer 'Labor' market segment

Human Immunodeficiency Virus – HIV

Medications for Pre-Exposure Prophylaxis (PrEP)

- **Recommendation:** clinicians offer pre-exposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.
 - ✓ USPSTF recommendation effective date: June 30, 2019.
 - ✓ Persons without HIV, and who are at high risk of HIV acquisition (as determined by the prescriber).
 - ✓ Opt-In to \$0 coverage available 1/1/2020. Requirement for coverage for plan year renewals that begin 7/1/2020 or after.
- Standard coverage
 - ✓ Generic Emtricitabine/TDF 200mg/300mg
 - ✓ Brand Truvada included in coverage until generic is available (anticipated fall 2020)
 - ✓ \$0 co-pay applied at point of service for persons without prescription claims for other antiretroviral drugs used for HIV treatment (lookback is 720 days)
 - ✓ Offering includes Co-Pay exception review criteria* for alternative therapies
- No age limitation is applied

*Standard review charges may apply based on client/PBM contract





**CHAMPIONS
FOR
BETTERSM**

